"Voronoi, a Biotech Specialized in Targeted Therapy Design and Development"

C797S Pipeline Value Estimated at 1.276 Trillion KRW
Exon 20 Value Estimated at 649 Billion KRW

[Asia Economy Reporter Hyungsoo Park] Hana Financial Investment analyzed Boronoi on the 13th as a biotech specialized in drug design.

Boronoi is a biotech company specializing in the design and development of targeted therapeutics. It has two wholly owned subsidiaries: Boronoi Bio, responsible for pharmaceutical synthesis and evaluation, and BTS Bio, which develops TPD. The total number of researchers working at Boronoi and its subsidiaries reaches 86.

Jaekyung Park, a researcher at Hana Financial Investment, introduced, "Boronoi has 56 medicinal chemistry experts responsible for drug structure design and synthesis," adding, "The company also has in-house laboratories capable of conducting cell and animal experiments."

He added, "Every year, about 4,000 chemical drugs are synthesized, and they have accumulated 550,000 experimental data points and animal experiment data from 18,000 animals."

Researcher Park explained, "The most important aspect in developing targeted therapeutics is selectivity," defining selectivity as "having appropriate binding affinity to the target protein while minimizing binding to non-target proteins."

He continued, "Increasing selectivity is essential to minimize side effects caused by binding to non-target proteins," emphasizing, "It determines the efficacy and safety of targeted therapeutics."

He analyzed, "Boronoi's main pipelines show excellent blood-brain barrier permeability," explaining, "This is because AI and data algorithms enable the identification of lead compounds (Hits) with superior blood-brain barrier permeability."

Furthermore, he said, "For substances with a molecular weight above 500 Da, it is difficult to predict permeability based on literature due to a lack of experimental data," adding, "Boronoi improves prediction accuracy by training on blood-brain barrier permeability experimental data from 4,000 internally synthesized compounds annually."

Researcher Park explained, "Boronoi can continuously derive candidate compounds based on its drug design capabilities," and "It has a strategy to increase the success rate through technology transfer."

He emphasized, "The value of Boronoi's C797S pipeline is estimated at 1.276 trillion KRW," and "The Exon 20 pipeline is estimated to be worth 649 billion KRW." He further explained, "Boronoi is developing multiple pipelines based on its drug design capabilities," and "Among the pipelines, the value was first assessed for the GDC pipeline, which is expected to have the highest probability of development success."

This content was produced with the assistance of AI translation services.